EGFR and lung carcinoma: For instance, EGFR blockade caused an enrichment of lung cancer stem-like cells through Notch-dependent signaling53 and co-targeting of these two pathways have shown anti-tumor efficacy with strong anti-stem cell effect.54 EGFR tyrosine kinase inhibitor-resistant lung cancer was also found to be responsive to the combined treatment of Notch inhibitors with EGFR inhibitors, gefitinib, or osimertinib.55 These studies further strengthen the concept of dual targeting of EGFR and Notch signaling in blocking tumor growth.